No black box warning on record for Cycloserine

As of the latest FDA labeling reviewed, Cycloserine (CYCLOSERINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Cycloserine medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Administration of cycloserine should be discontinued or the dosage reduced if the patient develops allergic dermatitis or symptoms of CNS toxicity, such as convulsions, psychosis, somnolence, depression, confusion, hyperreflexia, headache, tremor, vertigo paresis, or dysarthria. The toxicity of cycloserine is closely related to excessive blood levels (above 30 mcg/mL), as determined by hi

No black box warning on record for Cycloserine

Other warnings & precautions

WARNINGS Administration of cycloserine should be discontinued or the dosage reduced if the patient develops allergic dermatitis or symptoms of CNS toxicity, such as convulsions, psychosis, somnolence, depression, confusion, hyperreflexia, headache, tremor, vertigo paresis, or dysarthria. The toxicity of cycloserine is closely related to excessive blood levels (above 30 mcg/mL), as determined by hi

Cycloserine Black Box Warning

No black box warning on record for Cycloserine

Other warnings & precautions

Cycloserine Black Box Warning

No black box warning on record for Cycloserine

Other warnings & precautions